KCM
NRIX icon

Kennedy Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Kennedy Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Buy
724,508
+163,258
+29% +$2.78M 0.31% 100
2026
Q1 		$8.7M Buy
561,250
+300,046
+115% +$4.98M 0.18% 188
2025
Q4 		$4.96M Buy
261,204
+14,461
+6% +$208K 0.1% 298
2025
Q3 		$2.28M Sell
246,743
-11,073
-4% -$115K 0.05% 431
2025
Q2 		$2.94M Buy
257,816
+52,716
+26% +$570K 0.07% 379
2025
Q1 		$2.44M Buy
205,100
+90,477
+79% +$1.51M 0.06% 407
2024
Q4 		$2.16M Buy
114,623
+785
+0.7% +$18K 0.05% 499
2024
Q3 		$2.56M Buy
113,838
+53,985
+90% +$1.22M 0.06% 469
2024
Q2 		$1.25M Sell
59,853
-28,407
-32% -$442K 0.03% 569
2024
Q1 		$1.3M Sell
88,260
-72,751
-45% -$782K 0.03% 596
2023
Q4 		$1.66M Sell
161,011
-2,612
-2% -$17.9K 0.04% 522
2023
Q3 		$1.29M Buy
163,623
+107,719
+193% +$984K 0.03% 541
2023
Q2 		$558K Buy
+55,904
New +$570K 0.01% 599

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kennedy Capital Management's NRIX Position: Q2 2026 in Review

Kennedy Capital Management increased its Nurix Therapeutics (NRIX) stake by 29% in Q2 2026, buying an estimated $2.78M and bringing the position to 724,508 shares worth $17.6M. The position accounts for 0.31% of the portfolio, ranked #100.

Kennedy Capital Management first reported a position in NRIX in Q2 2023 and has held it in 13 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Kennedy Capital Management held 724,508 shares of Nurix Therapeutics worth $17.6M as of Q2 2026.
  • Kennedy Capital Management bought 163,258 Nurix Therapeutics shares in Q2 2026, an estimated $2.78M.
  • Nurix Therapeutics made up 0.31% of Kennedy Capital Management's portfolio in Q2 2026, its #100 holding.
  • Kennedy Capital Management first reported a position in Nurix Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.